309 related articles for article (PubMed ID: 30580099)
21. Defective fatty acid oxidation in mice with muscle-specific acyl-CoA synthetase 1 deficiency increases amino acid use and impairs muscle function.
Zhao L; Pascual F; Bacudio L; Suchanek AL; Young PA; Li LO; Martin SA; Camporez JP; Perry RJ; Shulman GI; Klett EL; Coleman RA
J Biol Chem; 2019 May; 294(22):8819-8833. PubMed ID: 30975900
[TBL] [Abstract][Full Text] [Related]
22. Trimethylamine N-oxide ameliorates hepatic damage including reduction of hepatic bile acids and cholesterol in
Miyata M; Takeda K; Nagira S; Sugiura Y
Int J Food Sci Nutr; 2024 Jun; 75(4):385-395. PubMed ID: 38690724
[TBL] [Abstract][Full Text] [Related]
23. Farnesoid X receptor regulates bile acid-amino acid conjugation.
Pircher PC; Kitto JL; Petrowski ML; Tangirala RK; Bischoff ED; Schulman IG; Westin SK
J Biol Chem; 2003 Jul; 278(30):27703-11. PubMed ID: 12754200
[TBL] [Abstract][Full Text] [Related]
24. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice.
Herrema H; Meissner M; van Dijk TH; Brufau G; Boverhof R; Oosterveer MH; Reijngoud DJ; Müller M; Stellaard F; Groen AK; Kuipers F
Hepatology; 2010 Mar; 51(3):806-16. PubMed ID: 19998408
[TBL] [Abstract][Full Text] [Related]
25. Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -/- mice versus hamsters.
Gardès C; Chaput E; Staempfli A; Blum D; Richter H; Benson GM
J Lipid Res; 2013 May; 54(5):1283-99. PubMed ID: 23431047
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of acyl-CoA synthetase-1 increases lipid deposition in hepatic (HepG2) cells and rodent liver in vivo.
Parkes HA; Preston E; Wilks D; Ballesteros M; Carpenter L; Wood L; Kraegen EW; Furler SM; Cooney GJ
Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E737-44. PubMed ID: 16705061
[TBL] [Abstract][Full Text] [Related]
27. Chronic sucralose consumption inhibits farnesoid X receptor signaling and perturbs lipid and cholesterol homeostasis in the mouse livers, potentially by altering gut microbiota functions.
Chi L; YifeiYang ; Bian X; Gao B; Tu P; Ru H; Lu K
Sci Total Environ; 2024 Apr; 919():169603. PubMed ID: 38272087
[TBL] [Abstract][Full Text] [Related]
28. Preservation of Acyl Coenzyme A Attenuates Pathological and Metabolic Cardiac Remodeling Through Selective Lipid Trafficking.
Goldenberg JR; Carley AN; Ji R; Zhang X; Fasano M; Schulze PC; Lewandowski ED
Circulation; 2019 Jun; 139(24):2765-2777. PubMed ID: 30909726
[TBL] [Abstract][Full Text] [Related]
29. The role of retinoic acid in hepatic lipid homeostasis defined by genomic binding and transcriptome profiling.
He Y; Gong L; Fang Y; Zhan Q; Liu HX; Lu Y; Guo GL; Lehman-McKeeman L; Fang J; Wan YJ
BMC Genomics; 2013 Aug; 14():575. PubMed ID: 23981290
[TBL] [Abstract][Full Text] [Related]
30. Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation.
Sheng L; Jena PK; Hu Y; Liu HX; Nagar N; Kalanetra KM; French SW; French SW; Mills DA; Wan YY
J Pathol; 2017 Dec; 243(4):431-441. PubMed ID: 28892150
[TBL] [Abstract][Full Text] [Related]
31. Hypocholesterolaemic effect of whole-grain highland hull-less barley in rats fed a high-fat diet.
Xia X; Li G; Song J; Zheng J; Kan J
Br J Nutr; 2018 May; 119(10):1102-1110. PubMed ID: 29759109
[TBL] [Abstract][Full Text] [Related]
32. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice.
Martin IV; Schmitt J; Minkenberg A; Mertens JC; Stieger B; Mullhaupt B; Geier A
Biol Chem; 2010 Dec; 391(12):1441-9. PubMed ID: 20868235
[TBL] [Abstract][Full Text] [Related]
33. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
[TBL] [Abstract][Full Text] [Related]
35. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
36. Microbiota-induced obesity requires farnesoid X receptor.
Parséus A; Sommer N; Sommer F; Caesar R; Molinaro A; Ståhlman M; Greiner TU; Perkins R; Bäckhed F
Gut; 2017 Mar; 66(3):429-437. PubMed ID: 26740296
[TBL] [Abstract][Full Text] [Related]
37. Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates.
Amano Y; Shimada M; Miura S; Adachi R; Tozawa R
Eur J Pharmacol; 2014 Jan; 723():108-15. PubMed ID: 24361308
[TBL] [Abstract][Full Text] [Related]
38. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
39. FXR an emerging therapeutic target for the treatment of atherosclerosis.
Mencarelli A; Fiorucci S
J Cell Mol Med; 2010 Jan; 14(1-2):79-92. PubMed ID: 20041971
[TBL] [Abstract][Full Text] [Related]
40. Sterol 12α-Hydroxylase Aggravates Dyslipidemia by Activating the Ceramide/mTORC1/SREBP-1C Pathway via FGF21 and FGF15.
Pathak P; Chiang JYL
Gene Expr; 2019 Nov; 19(3):161-173. PubMed ID: 30890204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
